сделай по следующим стандартам список литературы

В библиографическом списке приводятся фамилии всех авторов, если их не более четырех. Если авторов больше, то следует указать фамилии первых трех (!) авторов и далее написать «и др.» («et al.»).При описании статей из журналов данные указываются в следующем порядке: фамилии и инициалы авторов, название статьи, через // название журнала, год, том (если есть), номер, интервал страниц. Название журнала необходимо указать полностью! Элементы библиографической записи разделяются точкой. Крайне желательно указывать индекс DOI.

Примеры:

5. Fukayama H., Nasu M., Murakami S., Sugawara M. Examination of antithyroid effects of smoking products in cuitured thyroid follicles: Only thiocyanate is a potent antithyroid agent // Acta Endocrinologica. 1992. Vol. 127. No. 6. P. 520–525.
6. Мазанкова Л.Н., Горбунов С.Г., Самитова Э.Р. Значение интерферонотерапии при COVID-19 у детей // Детские инфекции. 2021. Т. 20, № 1. С. 34–38. DOI: 10.22627/2072-8107-2021-20-1-34-38.

вот список который надо привести к стандарту:

1. Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019 Jul;7(13):278. doi: 10.21037/atm.2019.04.13. PMID: 31392190; PMCID: PMC6642931.
2. Alizadeh Y, Saidi H, Saeedi V, Kamalzadeh L. Infantile-onset pompe disease: a case report emphasizing the role of genetic counseling and prenatal testing. BMC Pediatr. 2024 Mar 18;24(1):194. doi: 10.1186/s12887-024-04690-6. PMID: 38500078; PMCID: PMC10946141.
3. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, Zora M, Scalia S, Brando C, Curto AL, Marsana EM, Olivieri R, Vitale S, Duro G. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020 Aug 3;12(15):15856-15874. doi: 10.18632/aging.103794. Epub 2020 Aug 3. PMID: 32745073; PMCID: PMC7467391.
4. Karadağ Gürel A, Gürel S. To detect potential pathways and target genes in infantile Pompe patients using computational analysis. Bioimpacts. 2022;12(2):89-105. doi: 10.34172/bi.2022.23467. Epub 2022 Jan 22. PMID: 35411297; PMCID: PMC8905584.
5. Colburn R, Lapidus D. An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion. Front Pediatr. 2024 Jan 8;11:1221140. doi: 10.3389/fped.2023.1221140. PMID: 38274468; PMCID: PMC10810242.
6. De Filippi P, Saeidi K, Ravaglia S, Dardis A, Angelini C, Mongini T, Morandi L, Moggio M, Di Muzio A, Filosto M, Bembi B, Giannini F, Marrosu G, Rigoldi M, Tonin P, Servidei S, Siciliano G, Carlucci A, Scotti C, Comelli M, Toscano A, Danesino C. Genotype-phenotype correlation in Pompe disease, a step forward. Orphanet J Rare Dis. 2014 Aug 8;9:102. doi: 10.1186/s13023-014-0102-z. PMID: 25103075; PMCID: PMC4249737.
7. Stevens D, Milani-Nejad S, Mozaffar T. Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. Curr Treat Options Neurol. 2022 Nov;24(11):573-588. doi: 10.1007/s11940-022-00736-1. Epub 2022 Aug 4. PMID: 36969713; PMCID: PMC10035871.
8. Семячкина А.Н., Сухоруков В.С., Букина Т.М., Яблонская М.И., Меркурьева Е.С,, Харабадзе М.Н., Проскурина Е.А., Захарова Е.Ю., Брыдун А.В., Шаталов П.А., & Новиков П.В. (2014). Болезнь накопления гликогена, тип II (болезнь Помпе) у детей. Российский вестник перинатологии и педиатрии, 59 (4), 48-55.
9. de Faria DOS, 't Groen SLMI, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT, Bergsma AJ, Pijnappel WWMP. Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021 Feb;42(2):119-134. doi: 10.1002/humu.24148. Epub 2020 Dec 21. PMID: 33560568; PMCID: PMC7898817.
10. Niño MY, In 't Groen SLM, Bergsma AJ, van der Beek NAME, Kroos M, Hoogeveen-Westerveld M, van der Ploeg AT, Pijnappel WWMP. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat. 2019 Nov;40(11):1954-1967. doi: 10.1002/humu.23854. Epub 2019 Jul 29. PMID: 31254424; PMCID: PMC6851659.
11. Labella B, Cotti Piccinelli S, Risi B, Caria F, Damioli S, Bertella E, Poli L, Padovani A, Filosto M. A Comprehensive Update on Late-Onset Pompe Disease. Biomolecules. 2023 Aug 22;13(9):1279. doi: 10.3390/biom13091279. PMID: 37759679; PMCID: PMC10526932.
12. Malekkou A, Theodosiou A, Alexandrou A, Papaevripidou I, Sismani C, Jacobs EH, Ruijter GJG, Anastasiadou V, Ourani S, Athanasiou E, Drousiotou A, Grafakou O, Petrou PP. GAA variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing. Mol Genet Metab Rep. 2023 Aug 7;36:100997. doi: 10.1016/j.ymgmr.2023.100997. PMID: 37600231; PMCID: PMC10433214.
13. Niño MY, In't Groen SLM, de Faria DOS, Hoogeveen-Westerveld M, van den Hout HJMP, van der Ploeg AT, Bergsma AJ, Pijnappel WWMP. Broad variation in phenotypes for common GAA genotypes in Pompe disease. Hum Mutat. 2021 Nov;42(11):1461-1472. doi: 10.1002/humu.24272. Epub 2021 Sep 8. PMID: 34405923; PMCID: PMC9292902.
14. Herbert M, Case LE, Rairikar M, Cope H, Bailey L, Austin SL, Kishnani PS. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant. Mol Genet Metab. 2019 Feb;126(2):106-116. doi: 10.1016/j.ymgme.2018.08.009. Epub 2018 Aug 23. PMID: 30655185; PMCID: PMC9310053.
15. Xi H, Li X, Ma L, Yin X, Yang P, Zhang L. Infantile Pompe disease with intrauterine onset: a case report and literature review. Ital J Pediatr. 2022 Nov 21;48(1):187. doi: 10.1186/s13052-022-01379-3. PMID: 36411466; PMCID: PMC9677902.
16. Котлукова, Н. П., Михайлова, С. В., Букина, Т. М., & Захарова, Е. Ю. (2012). Младенческая форма болезни Помпе: клиника, диагностика и лечение. Нервно-мышечные болезни, (4), 66-74.
17. Leslie N, Bailey L. Pompe Disease. 2007 Aug 31 [updated 2023 Nov 2]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301438.
18. Marques JS. The Clinical Management of Pompe Disease: A Pediatric Perspective. Children (Basel). 2022 Sep 16;9(9):1404. doi: 10.3390/children9091404. PMID: 36138713; PMCID: PMC9497581.
19. Skvortsov V.V., Ponomareva A.R. Pompe disease. The Nurse, 2021; 5 (23): 51–53, DOI: https://doi.org/10.29296/25879979-2021-05-11
20. Desai AK, Smith PB, Yi JS, Rosenberg AS, Burt TD, Kishnani PS. Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease. Front Immunol. 2024 Jan 4;14:1301912. doi: 10.3389/fimmu.2023.1301912. PMID: 38250073; PMCID: PMC10798041.
21. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS. The emerging phenotype of late-onset Pompe disease: A systematic literature review. Mol Genet Metab. 2017 Mar;120(3):163-172. doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11. PMID: 28185884.
22. Сергей А.К. (2019). Болезнь Помпе с поздним началом: клиническая семиотика и дифференциальная диагностика. Нервные болезни, (3), 3-14. doi: 10.24411/2226-0757-2019-12119
23. van Kooten HA, Roelen CHA, Brusse E, van der Beek NAME, Michels M, van der Ploeg AT, Wagenmakers MAEM, van Doorn PA. Cardiovascular disease in non-classic Pompe disease: A systematic review. Neuromuscul Disord. 2021 Feb;31(2):79-90. doi: 10.1016/j.nmd.2020.10.009. Epub 2020 Nov 9. PMID: 33386209.
24. Lee NC, Chang KL, In 't Groen SLM, de Faria DOS, Huang HJ, Pijnappel WWMP, Hwu WL, Chien YH. Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening. J Pediatr. 2022 May;244:139-147.e2. doi: 10.1016/j.jpeds.2021.12.072. Epub 2022 Jan 4. PMID: 34995642.
25. Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, Labarthe F, Tardieu M, Chabrol B, Brassier A, Parini R, Parenti G, van der Beek NAME, van der Ploeg AT, van den Hout JMP; European Pompe Consortium project group on classic infantile Pompe disease. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022 Jan;6(1):28-37. doi: 10.1016/S2352-4642(21)00308-4. Epub 2021 Nov 22. PMID: 34822769.
26. Holzwarth J, Minopoli N, Pfrimmer C, Smitka M, Borrel S, Kirschner J, Muschol N, Hartmann H, Hennermann JB, Neubauer BA, Hobbiebrunken E, Husain RA, Hahn A. Clinical and Genetic Aspects of Juvenile Onset Pompe Disease. Neuropediatrics. 2022 Feb;53(1):39-45. doi: 10.1055/s-0041-1735250. Epub 2021 Dec 1. PMID: 34852371.
27. Pfrimmer C, Smitka M, Muschol N, Husain RA, Huemer M, Hennermann JB, Schuler R, Hahn A. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort. J Neuromuscul Dis. 2024;11(1):167-177. doi: 10.3233/JND-230164. PMID: 38043017; PMCID: PMC10789365.
28. Kenney-Jung D, Korlimarla A, Spiridigliozzi GA, Wiggins W, Malinzak M, Nichting G, Jung SH, Sun A, Wang RY, Al Shamsi A, Phornphutkul C, Owens J, Provenzale JM, Kishnani PS. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease. Mol Genet Metab. 2024 Feb;141(2):108119. doi: 10.1016/j.ymgme.2023.108119. Epub 2023 Dec 22. PMID: 38184429; PMCID: PMC11080415.
29. Басаргина, Е. Н., Архипова, Е. Н., & Ермоленко, В. С. (2014). Алглюкозидаза альфа - новый этап в терапии инфантильной (младенческой) формы болезни Помпе. Педиатрическая фармакология, 11 (5), 93-97.
30. Cerón-Rodríguez M, Castillo-García D, Acosta-Rodríguez-Bueno CP, Aguirre-Hernández J, Murillo-Eliosa JR, Valencia-Mayoral P, Escobar-Sánchez A, Salgado-Loza JL. Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: A case study. Mol Genet Genomic Med. 2022 Jul;10(7):e1957. doi: 10.1002/mgg3.1957. Epub 2022 May 9. PMID: 35532199; PMCID: PMC9266604.
31. Carter C, Boggs T, Case LE, Kishnani P. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa. Front Genet. 2024 Jan 19;15:1309146. doi: 10.3389/fgene.2024.1309146. PMID: 38313679; PMCID: PMC10834735.
32. Toscano A, Pollissard L, Msihid J, van der Beek N, Kishnani PS, Dimachkie MM, Berger KI, DasMahapatra P, Thibault N, Hamed A, Zhou T, Haack KA, Schoser B. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial. Mol Genet Metab. 2024 Feb;141(2):108121. doi: 10.1016/j.ymgme.2023.108121. Epub 2023 Dec 27. PMID: 38184428.
33. Roger AL, Sethi R, <PRESIDIO_ANONYMIZED_PERSON>, <PRESIDIO_ANONYMIZED_PERSON>, Bao-Dai J, Lai E, Biswas DD, El Haddad L, Strickland LM, Kishnani PS, ElMallah MK. What's new and what's next for gene therapy in Pompe disease? Expert Opin Biol Ther. 2022 Sep;22(9):1117-1135. doi: 10.1080/14712598.2022.2067476. Epub 2022 Apr 27. PMID: 35428407; PMCID: PMC10084869.
34. McFarlane HJ, Soni N. Pompe's disease and anaesthesia. Anaesthesia. 1986 Dec;41(12):1219-24. doi: 10.1111/j.1365-2044.1986.tb13007.x. PMID: 3468810.
35. Цветанова К.Т. (2017). Болезнь Помпе (Помпе) и анестезия. Науки Европы, (12-2 (12)), 115-119.